Table 6.

Comparison of features of EE in the current series with previous large literature around the world

	Current series	Muda R et al. (Malaysia/South-east Asia)	P and 95% C.I.	Ratra et al. (India/Asia)	P and 95% C.I.	Binder et al. (USA/North America)	P and 95% C.I.
n	173	143		61		34
Males (%)	96 (55.5)	59 (49.2)	0.26	36 (62.1)	0.37	19 (55.5)	0.98
Mean age (years)	25.41±20.46	52.6±15.1	<0.0001, −31.24-−23.14	34.6±14.9	0.002, −14.81-−3.56	63.3	-
Identification of primary source of infection (%)	56 (32.37)	90 (75)	<0.0001, 32.04%- 51.75%	31 (53.4)	0.003, 6.69%- 34.64%	33 (97)	<0.0001. 50.66%- 71.67%
Systemic symptoms identified (%)	41 (23.7)	84 (70)	<0.0001 35.79%- 55.27%	22 (37.9)	0.03, 1.14%- 27.99%	23 (67.64)	<0.0001, 25.78%- 58.34%
Complaints of blurry vision (%)	161 (93)	106 (74)	<0.0001, 10.89%- 27.23%	60 (98.4)	0.11	31 (92.6)	0.93
Blood culture positivity (%)	1 (0.57)	50 (42)	<0.0001, 33.22%- 49.63%	2 (5.88)	0.02, 0.3%- 18.52%	9 (33.33)	<0.0001, 19.08%- 49.57%
Urine culture positivity (%)	11 (6.35)	19 (41.3)	<0.0001, 25.91%- 43.6%	4 (11.6)	0.88	7 (25.9)	0.001, 5.97%- 38.5%
Vitreous culture positivity (%)	161 (93.06)	27 (22.3)	<0.0001, 61.79%- 77.42%	16 (47.05)	<0.0001, 29.11%- 69.88%	24 (70.58)	0.0001, 9.01%- 39.49%
Gram-negative etiology (%)	64 (37)	66 (80.8)	<0.0001, 33.11%- 52.36%	20 (58.82)	0.01, 3.64%- 38.13%	4 (11.76)	0.004, 8.88%- 35.49%
Fungal etiology (%)	24 (15)	16 (19.5)	0.3	5 (14.7)	0.96	14 (41.17)	0.0004, 10.16%- 43.38%
Vitrectomy done (%)	154 (89)	73 (51.4)	<0.0001, 27.83%- 46.58%	38 (62.3)	<0.0001, 14.31%- 39.82%	21 (61.7)	0.0001, 14.31%- 39.82%
Favorable functional outcome (%)	45 (26.01)	100 (73)	<0.0001, 28.71%- 48.76%	18 (29.5)	0.59	12 (35.29)	0.26
Favorable anatomic outcome (%)	76 (43.93)	No information	-	33 (54.09)	0.17
Rate of evisceration or enucleation (%)	9 (5.2)	6 (4.19)	0.67	12 (19.7)	0.0007, 5.33%- 26.39%	4 (11.76)	0.15